VBI Vaccines Partner Brii: Topline Interim Results of Phase 2 for Hepatitis B Combo

 

• BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at the end of treatment and 12 weeks follow up

• Significantly increased seroconversion rate is strongly associated with BRII-179 (VBI-2601) treatment and correlates with the increased rate of HBsAg loss

• Safety findings are similar to those of PEG-IFNα and BRII-179 (VBI-2601) as previously reported

https://finance.yahoo.com/news/vbi-vaccines-partner-brii-biosciences-120000803.html